Charles Schwab Investment Management Inc. Grows Position in Applied Therapeutics, Inc. (NASDAQ:APLT)

Charles Schwab Investment Management Inc. grew its stake in Applied Therapeutics, Inc. (NASDAQ:APLT) by 165.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 735,217 shares of the company’s stock after buying an additional 457,940 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Applied Therapeutics were worth $6,249,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Victory Capital Management Inc. bought a new position in shares of Applied Therapeutics during the 2nd quarter valued at approximately $54,000. Principal Financial Group Inc. bought a new position in shares of Applied Therapeutics in the second quarter worth approximately $54,000. SG Americas Securities LLC bought a new position in shares of Applied Therapeutics in the second quarter worth approximately $87,000. Intech Investment Management LLC purchased a new stake in shares of Applied Therapeutics in the third quarter worth $162,000. Finally, Algert Global LLC bought a new stake in shares of Applied Therapeutics during the 2nd quarter valued at $110,000. Hedge funds and other institutional investors own 98.31% of the company’s stock.

Applied Therapeutics Trading Up 2.5 %

NASDAQ:APLT opened at $1.24 on Thursday. The company has a market capitalization of $144.29 million, a P/E ratio of -0.77 and a beta of 1.77. The business’s 50-day moving average is $7.61 and its 200 day moving average is $6.29. Applied Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $10.62.

Analyst Upgrades and Downgrades

APLT has been the subject of several recent analyst reports. Leerink Partners upped their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Royal Bank of Canada lowered Applied Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $12.00 to $4.00 in a research note on Friday, November 29th. Citigroup cut their target price on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Robert W. Baird lowered their price target on Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a report on Friday, November 29th. Finally, UBS Group reaffirmed a “neutral” rating and set a $2.00 price objective (down from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.